Vaxcyte (NASDAQ:PCVX) CFO Sells 10,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 10,000 shares of Vaxcyte stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $53.00, for a total value of $530,000.00. Following the sale, the chief financial officer directly owned 104,395 shares of the company’s stock, valued at $5,532,935. This represents a 8.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vaxcyte Price Performance

NASDAQ PCVX traded up $0.77 during trading on Thursday, reaching $51.44. The company’s stock had a trading volume of 2,837,023 shares, compared to its average volume of 1,270,669. The stock has a market capitalization of $7.43 billion, a PE ratio of -7.48 and a beta of 1.24. The firm has a fifty day moving average of $53.56 and a 200 day moving average of $52.70. Vaxcyte, Inc. has a one year low of $29.08 and a one year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same quarter in the previous year, the company posted ($1.04) earnings per share. Research analysts expect that Vaxcyte, Inc. will post -7.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PCVX. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. Wall Street Zen downgraded shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. BTIG Research upped their target price on shares of Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $86.00.

Institutional Trading of Vaxcyte

A number of hedge funds have recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its stake in Vaxcyte by 156.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after buying an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Vaxcyte by 1,463.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after acquiring an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Vaxcyte by 33.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares during the period. Allworth Financial LP raised its position in Vaxcyte by 148.9% in the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after purchasing an additional 731 shares during the period. Finally, Aster Capital Management DIFC Ltd bought a new stake in Vaxcyte in the third quarter worth $45,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.